CytoDyn (CYDY) Convertible Debt (2011 - 2026)

CytoDyn's (CYDY) quarterly Convertible Debt came in at $27.2 million in Q1 2026, down 39.58% on a QoQ basis from $45.0 million in Q2 2024.

CytoDyn (CYDY) Convertible Debt (2011 - 2026) Analysis & Trends

CytoDyn (CYDY) has 14 years of Convertible Debt data on file, last reported at $27.2 million in Q1 2026.

Quarterly Convertible Debt changed N/A year-over-year to $27.2 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $27.2 million (changed N/A YoY) and the FY2024 annual result came in at $45.0 million, down 1.55% from the prior year.
Convertible Debt declined to $27.2 million in Q1 2026, from $45.0 million in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $45.8 million in Q4 2023 to a low of $27.2 million in Q1 2026.
A 4-year average of $42.2 million and a median of $44.9 million in 2023 frame the typical range for Convertible Debt.
Annual changes were most pronounced in 2022 — Convertible Debt surged 65.65% — and 2024, when it decreased 1.55%.
Tracing CYDY's Convertible Debt over 4 years: stood at $42.2 million in 2022, then gained by 8.61% to $45.8 million in 2023, then slipped by 1.81% to $45.0 million in 2024, then sank by 39.58% to $27.2 million in 2026.
The last three Convertible Debt figures came in at $27.2 million (Q1 2026), $45.0 million (Q2 2024), and $44.2 million (Q1 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	CytoDyn	258.01 Mn	258.01 Mn	-

Download Data